Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 vaccination response in patients with haematological malignancies
2021-001107-33Phase 4Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of elasomeran and tozinameran in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by Maastricht University Medical Center+. Primary endpoint: Anti-SARS-CoV-2 RBD antibody response after vaccination. Started Mar 2021; status: completed.
02
Drugs
elasomerantozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001107-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001107-33.